Syros Pharmaceuticals Inc (NASDAQ:SYRS) Stock Position Boosted by Samsara BioCapital LLC

Samsara BioCapital LLC boosted its position in shares of Syros Pharmaceuticals Inc (NASDAQ:SYRS) by 62.9% during the second quarter, Holdings Channel.com reports. The firm owned 1,726,603 shares of the company’s stock after buying an additional 666,665 shares during the quarter. Syros Pharmaceuticals makes up approximately 10.1% of Samsara BioCapital LLC’s portfolio, making the stock its 4th biggest position. Samsara BioCapital LLC’s holdings in Syros Pharmaceuticals were worth $15,228,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Bank of Montreal Can increased its position in shares of Syros Pharmaceuticals by 11,319.2% during the second quarter. Bank of Montreal Can now owns 2,969 shares of the company’s stock valued at $27,000 after acquiring an additional 2,943 shares during the last quarter. BNP Paribas Arbitrage SA acquired a new stake in shares of Syros Pharmaceuticals during the first quarter valued at about $48,000. A.R.T. Advisors LLC acquired a new stake in shares of Syros Pharmaceuticals during the second quarter valued at about $119,000. Bank of America Corp DE increased its position in shares of Syros Pharmaceuticals by 205.9% during the fourth quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock valued at $98,000 after acquiring an additional 11,711 shares during the last quarter. Finally, Algert Global LLC acquired a new stake in shares of Syros Pharmaceuticals during the second quarter valued at about $166,000. 82.08% of the stock is currently owned by institutional investors.

Shares of SYRS stock traded down $0.51 during trading on Wednesday, reaching $10.94. The company’s stock had a trading volume of 9,416 shares, compared to its average volume of 149,129. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.11 and a quick ratio of 8.11. The company has a market capitalization of $487.19 million, a price-to-earnings ratio of -5.78 and a beta of 1.60. The stock’s 50-day moving average price is $9.91 and its 200 day moving average price is $8.01. Syros Pharmaceuticals Inc has a 1-year low of $5.17 and a 1-year high of $13.16.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.06). The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.42 million. Syros Pharmaceuticals had a negative net margin of 3,137.55% and a negative return on equity of 79.79%. On average, sell-side analysts anticipate that Syros Pharmaceuticals Inc will post -1.94 EPS for the current fiscal year.

In related news, Director Richard A. Young sold 25,000 shares of Syros Pharmaceuticals stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $10.00, for a total value of $250,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Venture Fund Vii L.P. Arch sold 63,000 shares of Syros Pharmaceuticals stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $7.77, for a total transaction of $489,510.00. The disclosure for this sale can be found here. Insiders own 14.80% of the company’s stock.

A number of brokerages have weighed in on SYRS. BidaskClub upgraded shares of Syros Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. ValuEngine upgraded shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Zacks Investment Research upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Roth Capital began coverage on shares of Syros Pharmaceuticals in a research report on Friday, July 12th. They set a “buy” rating and a $17.00 price target for the company. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $16.03.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

See Also: Strike Price

Want to see what other hedge funds are holding SYRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syros Pharmaceuticals Inc (NASDAQ:SYRS).

Institutional Ownership by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.